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Introduction
Chronic periodontitis is arguably the most preva-
lent inflammatory disease affecting between 20% 
and 50% of adults worldwide.1–4 Chronic perio-
dontitis is the result of an aberrant host response 
to the oral microbial challenge in susceptible 
individuals.5 Porphyromonas gingivalis (P.g) is 
considered a key periodontal pathogen6 and P.g 
infection is highly prevalent in patients with 
chronic periodontitis.7 Chronic periodontitis and 
P.g infection have been hypothesized to contrib-
ute to the development of rheumatoid arthritis 
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Abstract
Background: Porphyromonas gingivalis (P.g) is unique among pathogens due to its ability 
to generate citrullinated proteins in an inflammatory milieu, potentially mediating the 
loss of immune tolerance, the production of anticitrullinated protein antibodies (ACPAs), 
and subsequently the development of rheumatoid arthritis (RA). Based on this hypothesis, 
we set out to investigate whether P.g is linked to ACPAs in a well-characterized German 
population.
Participants and methods: A total of 600 participants (292 women and 308 men with a mean 
age of 67 years) of the European Prospective Investigation into Cancer and Nutrition-Potsdam 
study were selected in 2013, and paired saliva and serum samples were collected. Salivary P.g 
DNA and serum anticyclic citrullinated peptide (anti-CCP2) levels were quantified by real-time 
polymerase chain reaction and anti-CCP2 enzyme-linked immunosorbent assay, respectively. 
In selected participants, additional ACPA fine-specificities were also analysed on a custom-
made multiplex peptide array.
Results: Among participants with C-reactive protein greater than 3.0 mg/l, a one-unit increase 
in P.g DNA was associated with an almost twofold increase in anti-CCP2 levels. Moreover, 
participants with high P.g DNA had on average approximately 2.8-times higher anti-CCP2 
levels when compared with participants with low P.g DNA, (Holm-adjusted p value = 0.01). 
Furthermore, citrullinated epitopes on α-enolase and vimentin were common ACPA 
reactivities among participants who also had high P.g DNA and elevated C-reactive protein.
Conclusions: Our study suggests that in specific subgroups of individuals with systemic 
inflammation, higher salivary P.g DNA is associated with elevated serum ACPA. These data 
support a role for P.g in the development of anticitrulline immunity.
Keywords: anticitrullinated protein autoantibodies, C-reactive protein, population studies, 
Porphyromonas gingivalis, saliva, serum
Received: 4 July 2019; revised manuscript accepted: 26 September 2019.
Correspondence to: 
Kolade Oluwagbemigun  
Nutritional Epidemiology, 
Department of Nutrition 
and Food Sciences, 
University of Bonn, 
Endenicher Allee 19b, 
Bonn, 53115, Germany
Department of 
Epidemiology, German 
Institute of Human 
Nutrition, Potsdam–
Nuthetal, Germany
koluwagb@uni-bonn.de
Tülay Yucel-Lindberg  
Periodontology Unit, 
Department of Dental 
Medicine, Karolinska 
Institutet, Stockholm, 
Sweden
Thomas Dietrich  
Department of Oral 
Surgery, School of 
Dentistry, University of 
Birmingham, Birmingham, 
UK
Gregory Tour  
Periodontology Unit, 
Department of Dental 
Medicine, Karolinska 
Institutet, Sweden
Department of Oral and 
Maxillofacial Surgery, 
Odense University 
Hospital, Denmark
Natalia Sherina  
Monika Hansson  
Karin Lundberg  
Rheumatology Unit, 
Department of Medicine, 
Karolinska Institutet, 
Stockholm, Sweden
Manuela Bergmann  
Heiner Boeing  
Department of 
Epidemiology, German 
Institute of Human 
Nutrition, Potsdam-
Nuthetal, Germany
*Shared senior authorship.
883152 TAB0010.1177/1759720X19883152Therapeutic Advances in Musculoskeletal DiseaseK Oluwagbemigun, T Yucel-Lindberg
research-article20192019
Original Research
Special CollectionWhen Rheumatology and Infectious Disease Come Together
Therapeutic Advances in Musculoskeletal Disease 11
2 journals.sagepub.com/home/tab
(RA).8 In fact, chronic periodontitis and P.g 
infection were shown to be associated with the 
prevalence of RA in a systematic review.9
P.g has been suggested as an aetiological link due 
to its unique feature among prokaryotes to express 
an arginine-specific proteinase, referred to as pep-
tidyl arginine deiminase enzyme (PPAD).10,11 The 
aetiological hypothesis is that P.g, through the 
actions of PPAD and gingipains, directly initiates 
protein citrullination (deamination of arginine 
residues) of both host and bacterial proteins, gen-
erating neoepitopes at mucosal surfaces.11,12 
Continual spreading of neoepitopes and somatic 
hypermutation in genetically susceptible individu-
als eventually results in a breakdown of immune 
tolerance, upregulation of inflammatory responses, 
development of autoimmunity and the subsequent 
production of high-affinity antibodies to citrulli-
nated proteins (ACPAs), a hallmark of RA.13,14
Local and systemic proinflammatory stimuli are 
essential for citrulline autoimmunity.15 Indeed, cit-
rullinated proteins and ACPAs are present in 
inflamed gingival tissue, suggesting local ACPA 
production, which may prime an individual for 
robust systemic ACPA production.16 Observational 
epidemiological studies are commensurate with 
this hypothesis, in that higher ACPA titres were 
reported in the periodontium and serum of patients 
with periodontitis when compared with healthy 
controls.17,18 A small clinical study also suggests 
that ACPA titres in patients with periodontitis may 
be specifically associated with oral exposure to 
P.g.19 Previously, we have shown elevated anti-P.g 
antibody levels in patients with RA who are posi-
tive for ACPAs, compared with controls, and that 
these antibodies precede the clinical onset of 
RA.20,21 This was confirmed in a meta-analysis.22 
Moreover, increased prevalence of periodontitis 
and P.g was shown recently in individuals at risk 
of being positive for ACPAs and unlike P.g, the 
abundance of another periodontal pathogen, 
Aggregatibacter actinomycetemcomitans was not 
increased in these individuals.23 In addition, oral 
exposure of rodents to P.g was found to trigger 
seropositive arthritis.24
Most of the evidence linking P.g to ACPA is from 
patient groups and clinical cohorts, and very few 
are based on the general population. Therefore, 
we set out to evaluate the association between the 
presence of P.g in saliva and serum ACPA levels 
in a well-characterized population-based cohort 
of apparently healthy individuals.
Participants and methods
Study design and population
Our study population was participants of the 
European Prospective Investigation into Cancer 
and Nutrition (EPIC)-Potsdam study. Details of 
the study design, recruitment, and follow up of the 
EPIC-Potsdam participants have been described 
previously.25,26 In brief, the EPIC-Potsdam partici-
pants were a cohort of 27,548 individuals, aged 
35–64 years, who were recruited between 1994 and 
1998 from the city of Potsdam, Germany and 
neighbouring communities. During this period, 
participants underwent baseline examinations, 
blood sampling, interviews, and completion of 
questionnaires about lifestyle characteristics and 
medical history. Every 2–3 years, questionnaires 
were sent to participants in order to obtain addi-
tional lifestyle and health data. All medical condi-
tions at baseline and during follow up were medically 
verified. The Ethics Committee of the State of 
Brandenburg, Germany, approved the study and all 
participants provided informed consent.
Between 2010 and 2012, 1472 active participants 
were selected using a rectangular sampling 
scheme to ensure an approximately uniform sam-
ple spread across sex and three age groups (35–
44, 45–54, and 55–64 years). All participants 
were invited to attend the study centre for specific 
clinical assessments. Of these participants, 815 
(55%) responded to the invitation and consented 
to participate. These 815 participants were re-
invited in 2013, and 728 (89%) consented. Paired 
blood and saliva samples were provided by 704 
(97%) out of the 728 participants.
Unstimulated saliva was collected at the study 
centre in the morning using the PSP® (Pre-
analytical Sample Processing) SalivaGene System 
kit (STRATEC Molecular GmbH, Berlin, and 
Germany) and processed. The sample collection, 
post-collection handling, processing, and storage 
of the samples were standardized. However, no 
presampling instructions were given to the partici-
pants. 30 ml of blood was also collected and pro-
cessed. Both samples were stored at −80°C until 
laboratory analysis. A schematic description of the 
EPIC-Potsdam study in phases leading to the cur-
rent study population is shown in Figure 1.
Isolation of genomic DNA from saliva
Genomic DNA (gDNA) was isolated from saliva 
using the QIAamp DNA mini kit (QIAGEN AB, 
K Oluwagbemigun, T Yucel-Lindberg et al.
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Sollentuna, Sweden) according to the manufac-
turer’s protocol. In brief, a 300-µl aliquot of saliva 
was centrifuged at 10,000 r.p.m. for 15 min to 
pellet the sample. Then, 180 µl of buffer ATL and 
20 µl of QIAGEN proteinase K were consecu-
tively added to the pelleted sample. The mixture 
was vortexed and incubated at 56°C for 30 min, 
and purified using ethanol-containing buffers. 
The gDNA was eluted in nuclease-free water, fol-
lowed by quantification and quality assessment 
(A260) with a NanoVue spectrophotometer (GE 
Healthcare Bio-Sciences, Uppsala, Sweden) and 
stored at −20°C until analysis.
Detection of P.g with quantitative real-time 
polymerase chain reaction
Quantitative real-time polymerase chain reaction 
(qPCR) was performed on the gDNA using the 
universal primer 16S to detect the presence of 
nonspecific bacterial DNA and with P.g-specific 
primer to detect the presence of P.g. Duplicate 
Figure 1. Flow chart of the current study population.
EPIC-Potsdam, European Prospective Investigation into Cancer and Nutrition-Potsdam.
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samples were assayed in a total volume of 20 µl, 
containing 40 ng of the template gDNA solution, 
TaqMan Universal PCR Master Mix 2× (Applied 
Biosystems, Carlsbad, USA), and the specific set 
of primers (final concentration 18 µM) and probe 
(final concentration 5 µM; Cybergene AB, 
Sweden). P.g primers were: forward –GCG CTC 
AAC GTT CAG CC; reverse: CAC GAA TTC 
CGC CTG C; and probe: 6FAM CAC TGA 
ACT CAA GCC CGG CAG TTT CAA–
TAMRA, and the 16s rDNA (universal) were for-
ward: TGG AGC ATG TGG TTT AAT TCG 
A; reverse –TGC GGG ACT TAA CCC AAC A; 
and probe: 6FAM CAC GAG CTG ACG ACA 
RCC ATG CA–TAMRA.27
The 7500 Fast Real-Time PCR System (Applied 
Biosystems) was used for amplification and detec-
tion of P.g. After an initial incubation step of 
2 min at 50°C and denaturation for 10 min at 
95°C, 40 PCR cycles (95°C for 15 s, 60°C for 
1 min) were performed. The relative quantity of 
P.g was calculated as the fold difference in mean 
cycle threshold value of the P.g DNA relative to 
the mean cycle threshold value of the total bacte-
rial DNA. DNA isolated from P.g strain ATCC 
33277 was used as the positive control.
Detection and quantification of ACPAs
Serum samples were screened for the presence of 
ACPA immunoglobulin (Ig)G, using the 
Immunoscan CCPlus® enzyme-linked immuno-
sorbent assay, from Euro-Diagnostica, Malmö, 
Sweden, according to the manufacturer’s instruc-
tions. In addition, sera from participants with anti-
CCP2 antibody levels ⩾25 arbitrary units (AU)/ml 
(i.e. considered as anti-CCP2 antibody positive, 
according to the kit instructions) and an equal 
number of randomly selected participants with 
anti-CCP2 antibody levels <25 AU/ml (i.e. anti-
CCP2 negative) were further analysed for the pres-
ence of ACPA fine-specificities using a custom- 
made microarray based on the ImmunoCAP ISAC 
microarray system (ThermoFisher Scientific, 
Phadia AB, Uppsala, Sweden), as previously 
described.28 We investigated 10 citrullinated pep-
tides derived from four different human proteins 
(fibrinogen, vimentin, filaggrin, and alpha- enolase) 
and 1 additional citrullinated peptide derived from 
PPAD, their arginine-containing control peptides, 
and 17 other autoantibody reactivities. The cut-off 
values for positivity (for each ACPA fine-specific-
ity) were based on the 98th percentile cut-off 
among healthy controls. Supplemental Tables 1 
and 2 provide details of the citrullinated and non-
citrullinated antigens respectively.
Measurement of serum markers of systemic 
inflammation
Circulating levels of two markers of inflammation, 
C-reactive protein (CRP) and white blood cell 
(WBC; leukocyte) count, was measured. CRP 
was measured using a high-sensitivity immunotur-
bidimetric assay and expressed in mg/l. WBCs 
were measured by fluorescence flow cytometric 
method and expressed in Gpt/l.
Assessments of covariates
Information on sociodemographic characteristics, 
anthropometry, lifestyle, current medications 
(within 7 days), including antibiotics, nonsteroidal 
anti-inflammatory drugs (NSAIDs), and synthetic 
or biological disease-modifying antirheumatic 
drugs (DMARDs) were also reported. These 
covariates were ascertained with the use of ques-
tionnaire at baseline or during follow up. 
Importantly, participants were asked if they had 
ever been diagnosed with periodontitis and rheu-
matic diseases. These data are the status of the par-
ticipants as of 2013. Details of covariates are 
available in supplemental text.
Statistical analyses
From the initial 704 individuals, we excluded 104 
because of low gDNA levels that were insufficient 
for P.g quantification. There was no significant 
difference between these individuals and the 600 
participants with sufficient gDNA (Supplemental 
Table 3). Using tertiles, 600 participants were 
categorized into three groups of low, moderate, 
and high P.g according to the relative quantity of 
P.g. For normally distributed continuous varia-
bles, non-normally distributed continuous varia-
bles, and categorical variables, one-way analysis 
of variance, Kruskal–Wallis nonparametric test, 
and Chi-square tests were used as statistical tests 
for differences across P.g groups, respectively.
We determined the relation between P.g and anti-
CCP2 IgG by fitting Tweedie generalized linear 
models (details in supplemental text). The Tweedie 
generalized linear model is appropriate for model-
ling semicontinuous dependent variables29 (anti-
CCP2 IgG in the current study). Our independent 
variable, P.g fold difference was modelled in two 
ways: continuously and categorized into tertiles. At 
K Oluwagbemigun, T Yucel-Lindberg et al.
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first, we investigated whether the association 
between P.g and anti-CCP2 varied across sub-
groups of age, sex, body mass index, smoking sta-
tus, periodontitis status, rheumatic diseases, CRP, 
and WBC count (details of subgroups in supple-
mental text) by including a product term between 
P.g and each variable in univariate analysis. 
Afterwards, we controlled for confounding by 
adjusting for covariates derived using directed acy-
clic graphs. Overall, we had four models: model 1 
with P.g only, and three multivariable models 
(models 2–4; adjustment sets in supplemental text). 
The beta estimates were exponentiated as relative 
risk (RR). The RR of the continuously modelled 
P.g was interpreted unit change in anti-CCP2 asso-
ciated with one-unit change in the fold difference of 
P.g. The categorically modelled P.g was interpreted 
as the ratio of the mean of anti-CCP2 between par-
ticipants with either high or moderate P.g com-
pared with the reference category, low P.g. These 
P.g group comparisons were adjusted for multiple 
comparisons using the Holm method. We also 
assessed the robustness of these analyses by exclud-
ing participants with myocardial infarction, stroke, 
and antibiotics, NSAID and DMARD use. 
Additionally, we investigated the nonlinear associa-
tion between P.g and anti-CCP2 using restricted 
cubic spline regression adjusted for covariates in 
model 4. Anti-CCP2 was transformed using the 
Box–Cox method (details in supplemental text).
Finally, for each individual within the subsets of 
participants that were positive for anti-CCP2 and 
equal numbers of randomly selected participants 
who were negative for anti-CCP2, we reported 
the presence (and number) or absence of addi-
tional antibody reactivities, the number of ACPA/
non-ACPA antibody reactivities, the quantity of 
P.g, CRP level, rheumatic disease, and the use of 
DMARDs or NSAIDs.
All statistical analyses were performed using SAS 
Enterprise Guide, version 6.1 (SAS Institute Inc., 
Cary, NC, USA). For all analysis, p ⩽ 0.05 was 
considered statistically significant.
Results
Characteristics of the study population
The age range of the final study population 
(n = 600, comprising 292 women and 308 men) 
was 47–82 years (mean age is 67 years with a stand-
ard deviation of 8.32). As shown in Table 1, across 
groups of increasing P.g, there was increasing sport 
time, higher alcohol consumption, a higher prev-
alence of type 2 diabetes mellitus (T2DM), and a 
higher leucocyte count. Conversely, there was a 
lower proportion of higher-grade professionals. 
No difference was observed regarding other char-
acteristics. Overall, 11 participants, correspond-
ing to 2% of the study population, were positive 
for the anti-CCP2 antibody. The majority of the 
individuals who were positive for the anti-CCP2 
antibody (n = 6) were found in the subset with a 
high P.g (Table 1).
Multivariable analyses of the association 
between quantity of P.g and anti-CCP2 IgG levels
The interaction term of P.g (both as continuous 
and categorical variable) and CRP group on the 
continuously modelled dependent variable, anti-
CCP2 IgG, was significant (p for interac-
tion = <0.01). This significant interaction term 
indicates that the association between P.g and 
anti-CCP2 IgG depends on CRP group. None of 
the interaction terms of P.g with other covariates 
were significant. Therefore, we fitted regression 
models separately for each CRP category and 
effect estimates, and RRs were presented as such. 
For each CRP category CCP2 model, the good-
ness of fit, Pearson’s Chi-square statistic divided 
by the degrees of freedom was close to one (1.25 
for CRP >3.0 mg/l, 1.62 for CRP 1.0–3.0 mg/l, 
and 1.86 for CRP <1.0 mg/l) showing that all 
specified CCP2 models fitted the data well.
Among participants with CRP >3.0 mg/l, in the 
fully adjusted model, a one-unit increase in the 
fold difference of P.g was associated with an 
almost twofold increase in anti-CCP2 IgG levels. 
Moreover, when compared with participants with 
low P.g, participants with high P.g had on average 
approximately 2.8 times higher anti-CCP2 IgG 
levels [RR = 2.82; 95% confidence interval (CI): 
1.60–9.11, Holm-adjusted p value = 0.01; Table 2]. 
Other covariates significantly associated with lev-
els of anti-CCP2 IgG were smoking and educa-
tion. Specifically, there was a threefold risk of 
elevated anti-CCP2 IgG levels among ever-smok-
ers when compared with nonsmokers (RR = 3.24; 
95% CI: 1.72–4.26, p = 0.01), and a threefold risk 
of elevated anti-CCP2 IgG levels among those 
with technical school educational attainment 
when compared with those with a university 
degree (RR = 2.61; 95% CI: 1.23–3.72, p = 0.02).
On the contrary, in groups of CRP 1.0–3.0 mg/l and 
CRP < 1.0 mg/l, there was no association between 
Therapeutic Advances in Musculoskeletal Disease 11
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continuously modelled P.g and anti-CCP2 anti-
body levels. Similarly, there was no difference 
between the moderate and high P.g when compared 
with low P.g (Table 2). In addition, no covariates 
were significantly associated with levels of anti-
CCP2 IgG in both groups. Further, there was no 
evidence of nonlinear associations between P.g and 
anti-CCP2 in both groups (Figures 2 and 3).
Table 1. Characteristics of the study population (N = 600).
Quantity of Porphyromonas gingivalis  
 Low Moderate High p value
Characteristics (N = 200) (N = 200) (N = 200)  
Women, N (%) 94 (47) 101 (51) 97 (49) NS
Men, N (%) 106 (53) 99 (49) 103 (51) NS
Age (years), M (SD) 67 (8.05) 67 (8.81) 67 (8.12) NS
Body mass index (kg/m2), M (SD) 27.38 (4.83) 27.22 (3.92) 27.56 (4.04) NS
Vocational training or less, N (%) 76 (38) 68 (34) 69 (35) NS
Higher-grade professionals, N (%) 56 (28) 54 (27) 47 (24) <0.01
Sport (hours/week), M (SD) 4.74 (6.21) 5.18 (5.69) 5.44 (9.99) 0.04
Ever-smokers, N (%) 112 (56) 99 (50) 107 (54) NS
Cigarettes/daya (N), M (SD) 11 (6.85) 11 (7.39) 9 (5.94) NS
Alcohol (g/day), M (SD) 11.51 (15.43) 12.56(15.30) 13.06(16.54) 0.03
Periodontitis, N (%) 66 (33) 79 (40) 69 (35) NS
Rheumatic diseases, N (%) 25 (13) 21 (11) 24 (13) NS
Type 2 diabetes mellitus, N (%) 16 (8) 18 (9) 23 (12) 0.02
Myocardial infarction, N (%) 9 (5) 2 (1) 7 (4) NS
Stroke, N (%) 3 (2) 5 (3) 5 (3) NS
Cancer, N (%) 2 (1) 1 (1) 4 (2) NS
DMARD, N (%) 8 (4) 3 (2) 9 (5) NS
Antibiotics, N (%) 2 (1) 2 (1) 0 (0) NS
NSAID, N (%) 24 (12) 15 (8) 26 (13) NS
Leucocyte (Gpt/l), M (SD) 5.86 (1.46) 5.96 (1.52) 6.08 (1.56) 0.05
C-reactive protein (mg/l), M (SD) 3.32 (7.30) 2.77 (4.06) 2.79 (3.14) NS
Anti-CCP2 IgG positiveb, N (%) 3 (2) 2 (1) 6 (3) NS
Anti-CCP2, second generation anticyclic citrullinated peptides antibody; AU, arbitrary units; DMARD, disease-modifying 
antirheumatic drug; ever-smokers, former smokers and current smokers; IgG, immunoglobulin G; M, mean; NS, 
nonsignificant at p value < 0.05; NSAID, nonsteroidal anti-inflammatory drug; P.g, Porphyromonas gingivalis; SD, standard 
deviation.
aNumber of cigarettes of current smokers.
bAnti-CCP2 IgG ⩾25 AU/ml.
Detection of P.g DNA was performed using real-time PCR analysis. The relative quantity of P.g was calculated as the fold 
difference in mean cycle threshold value of the P.g DNA relative to the mean cycle threshold value of the total bacterial 
DNA. P.g quantity (fold difference) was categorized into low, moderate and high, according to tertiles.
K Oluwagbemigun, T Yucel-Lindberg et al.
journals.sagepub.com/home/tab 7
Ta
bl
e 
2.
 M
ul
tiv
ar
ia
bl
e 
an
al
ys
es
 o
f t
he
 a
ss
oc
ia
tio
n 
be
tw
ee
n 
qu
an
tit
y 
of
 P
.g
 D
N
A
 a
nd
 a
nt
i-
C
C
P
2 
an
tib
od
y 
le
ve
ls
.
A
nt
i-
C
C
P
2 
Ig
G
 a
nt
ib
od
y 
le
ve
ls
 (A
U
/m
l)
 
M
od
el
 1
M
od
el
 2
M
od
el
 3
M
od
el
 4
C
R
P
R
R
95
%
 C
I
R
R
95
%
 C
I
R
R
95
%
 C
I
R
R
95
%
 C
I
>
3.
0 
m
g/
l (
N
 =
 1
51
)
P
.g
 (c
on
tin
uo
us
)
4.
07
1.
96
–8
.4
6
2.
54
1.
32
–4
.8
6
1.
98
1.
12
–3
.3
9
1.
99
1.
15
–3
.4
0
 
P
.g
 (g
ro
up
s)
Lo
w
 (N
 =
 4
8)
1.
00
R
ef
.
1.
00
R
ef
.
1.
00
R
ef
.
1.
00
R
ef
.
 
M
od
er
at
e 
(N
 =
 4
9)
1.
37
0.
51
 to
 3
.6
7
1.
38
0.
56
 to
 3
.4
0
1.
26
0.
59
 to
 2
.7
0
1.
34
0.
61
 to
 2
.9
6
 
H
ig
h 
(N
 =
 5
4)
8.
02
3.
05
–2
1.
10
4.
92
1.
98
–1
2.
23
3.
26
1.
45
–7
.3
1
2.
82
1.
60
–9
.1
1*
1.
0–
3.
0 
m
g/
l (
N
 =
 2
64
)
P
.g
 (c
on
tin
uo
us
)
1.
28
0.
73
–2
.2
2
1.
19
0.
70
–2
.0
3
1.
26
0.
76
–2
.0
8
1.
30
0.
78
–2
.1
5
 
P
.g
 (g
ro
up
s)
Lo
w
 (N
 =
 7
9)
1.
00
R
ef
.
1.
00
R
ef
.
1.
00
R
ef
.
1.
00
R
ef
.
 
M
od
er
at
e 
(N
 =
 9
1)
1.
05
0.
51
–2
.1
4
1.
02
0.
50
–2
.0
5
1.
12
0.
58
–2
.1
9
1.
14
0.
59
–2
.2
3
 
H
ig
h 
(N
 =
 9
4)
1.
55
0.
76
–3
.1
6
1.
40
0.
69
–2
.8
2
1.
42
0.
72
–2
.8
0
1.
49
0.
74
–2
.9
7
<
 1
.0
 m
g/
l (
N
 =
 1
85
)
P
.g
 (c
on
tin
uo
us
)
0.
88
0.
54
–1
.4
4
0.
87
0.
53
–1
.4
2
0.
79
0.
45
–1
.3
3
0.
76
0.
45
–1
.3
0
 
P
.g
 (g
ro
up
s)
Lo
w
 (N
 =
 7
3)
1.
00
R
ef
.
1.
00
R
ef
.
1.
00
R
ef
.
1.
00
R
ef
.
 
M
od
er
at
e 
(N
 =
 6
0)
0.
83
0.
51
–1
.3
4
0.
82
0.
50
–1
.3
3
0.
76
0.
44
–1
.3
1
0.
77
0.
45
–1
.2
9
 
H
ig
h 
(N
 =
 5
2)
0.
94
0.
57
–1
.5
6
0.
93
0.
56
–1
.5
5
0.
82
0.
46
–1
.4
6
0.
75
0.
43
–1
.3
2
M
od
el
 1
: u
na
dj
us
te
d;
 m
od
el
 2
: m
od
el
 1
 a
dj
us
te
d 
fo
r 
ag
e 
(c
on
tin
uo
us
), 
se
x,
 b
od
y 
m
as
s 
in
de
x 
(c
on
tin
uo
us
); 
m
od
el
 3
: m
od
el
 2
 a
dj
us
te
d 
fo
r 
ed
uc
at
io
n 
(t
hr
ee
 g
ro
up
s)
, o
cc
up
at
io
n 
(fo
ur
 
gr
ou
ps
), 
w
or
k 
ho
ur
s 
(s
ix
 g
ro
up
s)
, h
ou
rs
 o
f s
po
rt
 p
er
 w
ee
k 
(c
on
tin
uo
us
), 
al
co
ho
l (
co
nt
in
uo
us
), 
sm
ok
in
g 
st
at
us
 (t
w
o 
gr
ou
ps
); 
m
od
el
 4
: m
od
el
 3
 a
dj
us
te
d 
fo
r 
ty
pe
 2
 d
ia
be
te
s 
m
el
lit
us
 a
nd
 
ca
nc
er
.
A
nt
i-
C
C
P
2,
 s
ec
on
d 
ge
ne
ra
tio
n 
an
tic
yc
lic
 c
itr
ul
lin
at
ed
 p
ep
tid
es
 a
nt
ib
od
y;
 A
U
, a
rb
itr
ar
y 
un
it;
 C
I, 
co
nf
id
en
ce
 in
te
rv
al
; C
R
P
, C
-r
ea
ct
iv
e 
pr
ot
ei
n;
 Ig
G
, i
m
m
un
og
lo
bu
lin
 G
; P
.g
, P
or
ph
yr
om
on
as
 
gi
ng
iv
al
is
; R
ef
., 
re
fe
re
nc
e;
 R
R
, r
el
at
iv
e 
ri
sk
.
*S
ig
ni
fic
an
tl
y 
di
ff
er
en
t f
ro
m
 lo
w
 P
.g
. (
H
ol
m
-a
dj
us
te
d 
p 
va
lu
e 
= 
0.
02
).
Therapeutic Advances in Musculoskeletal Disease 11
8 journals.sagepub.com/home/tab
In sensitivity analyses, excluding participants with 
myocardial infarction, stroke and those who 
reported intake of antibiotics did not affect the 
results (data not shown). Moreover, excluding 
participants with CRP ⩾ 10.0 mg/l (as a marker of 
acute inflammation) did not affect the results 
either. Interestingly, when we excluded all 11 indi-
viduals who were positive for anti-CCP2, as well as 
those using NSAIDs and DMARDs; there still 
were higher anti-CCP2 IgG levels among partici-
pants with high P.g when compared with those 
with low P.g, within the group with CRP >3.0 mg/l.
Comparison of individuals positive and negative 
for anti-CCP2 with respect to additional 
autoantibody reactivities
Overall, 5 out of the 10 individuals who were pos-
itive for anti-CCP2 (1 was excluded due to 
technical reasons) had at least one additional 
autoantibody reactivity, while 4 individuals out of 
the 11 randomly selected individuals who were 
negative for anti-CCP2 had at least one addi-
tional autoantibody reactivity (Table 3). Antibody 
reactivities corresponding to different ACPA fine-
specificities were only detected in individuals who 
were positive for anti-CCP2. Antibodies against 
citrullinated α-enolase (anti-CEP-15–21 IgG) and 
citrullinated vimentin (anti-Cit-Vim60–75 IgG) 
constituted the most commonly detected ACPAs, 
and were present in four out of five individuals 
who were double positive for anti-CCP2/ACPA 
fine-specificity. Moreover, these four individuals 
also had a high quantity of P.g and high CRP lev-
els (>3.0 mg/l). In addition, three out of the five 
individuals who were double positive for anti-
CCP2/ACPA fine-specificity used DMARDs or 
NSAIDs, and three reported a rheumatic disease. 
Figure 2. Restricted cubic spline regression graph to model nonlinear association among participants with 
CRP between 1.0 and 3.0 mg/l.
Beta coefficient and 95% pointwise confidence band (dotted lines). Estimate was adjusted for age, sex, body mass index, 
education, occupation and work hours, smoking, alcohol, sport hours, type 2 diabetes mellitus, and cancer. Anti-CCP2 was 
transformed by a power of 0.08. The p value for nonlinear association was computed using the Wald Chi-square test.
CCP2, cyclic citrullinated peptide; CRP, C-reactive protein; IgG, immunoglobulin G; P.g, Porphyromonas gingivalis.
Figure 3. Restricted cubic spline regression graph to model nonlinear association among participants with 
CRP < 1.0 mg/l.
Beta coefficient and 95% pointwise confidence band (dotted lines). Estimate was adjusted for age, sex, body mass index, 
education, occupation and work hours, smoking, alcohol, sport hours, type 2 diabetes mellitus, and cancer. Anti-CCP2 was 
transformed by a power of 0.08. The p value for nonlinear association was computed using the Wald Chi-square test.
CCP2, cyclic citrullinated peptide; CRP, C-reactive protein; IgG, immunoglobulin G; P.g, Porphyromonas gingivalis.
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Table 3. Comparison of individuals positive for anti-CCP2 and randomly selected individuals negative for anti-CCP2.
Study 
participants
Additional 
autoantibody 
reactivities
anti-CCP2 
(AU/ml)
Name of autoantibody 
(number of ACPAs 
versus non-ACPAs)
P.g 
quantity
Rheumatic 
diseases 
(yes/no)
CRP 
(mg/l)
DMARD 
(yes/no)
NSAID 
(yes/no)
Anti-CCP2 
positive 
(N = 10)
Negative 27.24 None Moderate No 1.3 No No
 Negative 33.01 None Low No 1.2 No No
 Positive 567 Cit-Fil307–324,
Cit-Vim60–75, Cit-Fibß36–52,
Cit-Fibα580–600, CEP-15–21 
(5/0)
High No 3.8 No No
 Positive 500.93 Cit-Vim60–75, Cit-Vim2–17,
CEP-15–21, CPP-3121–139 
(4/0)
High No 4.1 Yes No
 Negative 47.79 None High Yes 0.7 Yes Yes
 Negative 57.21 None Low No 0.4 No No
 Positive 63.28 Cit-Fil307–324 (1/0) Low Yes 1.3 No No
 Negative 43.28 None Moderate No 0.9 No No
 Positive 129.87 Cit-Vim60–75,
Cit-Fibß(Cit-R)62–81a,
CEP-15–21, CPP-3121–139, 
dsDNA,
U1 RNP-C (4/2)
High Yes 18.5 Yes Yes
 Positive 94.76 CEP-15–21, Cit-Vim60–75 
(2/0)
High Yes 5.9 No Yes
Anti-CCP2 
negative 
(N = 11)
Negative 0 None Low No 16.0 No Yes
 Positive 10.8 dsDNA (0/1) Low No 2.5 No No
 Negative 0 None Low No 0.6 No No
 Negative 0 None Low No 1.3 No No
 Negative 0 None High No 4.8 No No
 Positive 19.49 Ro60/SSA (0/1) Moderate No 3.9 No No
 Negative 0 None Moderate No 0.7 No No
 Positive 2.72 SmBB (0/1) Moderate No 2.9 No No
 Negative 0 None Low No 11.9 No No
 Negative 0 None High No 0.2 No No
 Positive 0 dsDNA (0/1) High No 1.7 No No
AU, arbitrary unit; CCP, cyclic citrullinated peptide; CEP, citrullinated α-enolase peptide; Cit-Fib, citrullinated fibrinogen; Cit-Fil, citrullinated 
filaggrin; Cit-Vim, citrullinated vimentin; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; dsDNA, double-stranded DNA; 
NSAID, nonsteroidal anti-inflammatory drug; P.g, Porphyromonas gingivalis; Ro60/SSA, 60 kD RNA-associated protein; SmBB, small nuclear 
ribonucleoprotein-associated protein BB ribonucleoprotein; U1 RNP-C, human recombinant RNP-C protein. 
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One of these individuals was also positive for non-
ACPA autoantibodies, directed against double-
stranded DNA and U1 RNP-C complex protein. 
The individuals who were positive for anti-CCP2 
and negative for the ACPA fine-specificities 
(CCP2+ACPA−) had relatively lower anti-CCP2 
IgG levels compared with individuals who were 
positive for both anti-CCP2 and ACPA fine-spe-
cificities (CCP2+ACPA+). Moreover, individuals 
who were positive for anti-CCP2 ‘P.g high’ when 
compared with individuals who were positive for 
anti-CCP2 ‘P.g low’ generally had rheumatic dis-
ease, high CRP, and used DMARDs or NSAIDs 
(Table 3).
No ACPAs were detected among 11 randomly 
selected individuals who were negative for anti-
CCP2. Antibody reactivities in this subset 
included double-stranded DNA, 60 kD RNA-
associated protein, and small nuclear ribonucleo-
protein-associated protein BB. In addition, none 
of these individuals reported a rheumatic disease 
or DMARD use (Table 3).
Discussion
In this study of 600 individuals from a general 
population-based study cohort, we found a posi-
tive association between increasing quantity of 
salivary P.g DNA and serum anti-CCP2 IgG lev-
els, after adjusting for various covariates. 
Specifically, this association was confined to indi-
viduals with systemic inflammation, CRP >3 mg/l. 
We also found that those individuals who were 
positive for a number of ACPA fine-specificities 
also demonstrated a higher quantity of salivary 
P.g and higher CRP levels when compared with 
individuals who were negative for ACPAs.
Our data demonstrating an association between 
P.g DNA and ACPAs support the aetiological 
hypothesis first proposed by Rosenstein and col-
leagues13 that P.g infection plays a causative role in 
the development of ACPAs. This hypothesis was 
also supported by a number of other reports pin-
pointing a link between P.g infection and ACPA-
positive RA. Some of these studies reported an 
association between the presence and abundance 
of P.g and anti-CCP2 antibodies,18 while other 
studies,30–32 including our recent publications20,21 
and a recent meta-analysis22 reported a link 
between anti-P.g antibody levels and ACPAs, and 
yet others reported an association between clinical 
periodontitis and ACPAs.33–35 Mikuls and col-
leagues30 additionally reported an association 
between anti-P.g antibody levels and CRP, sug-
gesting that P.g infection influence both innate and 
adaptive immune responses. However, in other 
studies no relationship between anti-CCP2 and 
P.g abundance,36,37 anti-P.g antibody levels,38,39 
and clinical periodontitis alone40 was reported.
In relation to this ambiguity, elevated anti-CCP2 
antibody levels were observed in patients with 
periodontitis and dental plaque P.g, as compared 
with patients with periodontitis without dental 
plaque P.g and healthy controls,18 suggesting that 
the actual presence of P.g, rather than the severity 
of the periodontal lesion, is crucial in the relation-
ship with ACPAs and ACPA-positive RA. This 
notion was also brought forward in our recent 
studies, where we were unable to identify a link 
between periodontitis and ACPA-positive RA,41 
but in the same RA cohort, we could demonstrate 
elevated anti-P.g antibody levels in ACPA-
positive RA compared with both controls and 
ACPA-negative RA.20 Based on data from these 
studies, we concluded that the previously reported 
link between periodontitis and RA could be 
accounted for by P.g infection. Moreover, it has 
been suggested that P.g infection contributes to 
the overall increase in ACPA seropositivity in 
individuals without RA.24,42,43
Importantly, the association between the pres-
ence of P.g DNA and higher serum anti-CCP2 
antibody levels among individuals with high CRP 
in our study is noteworthy, given the evidence 
that P.g contributes to a systemic inflammatory 
milieu,44 and that citrullination of proteins is 
known to occur in response to inflammation;15 
this may foster the generation of ACPAs in genet-
ically susceptible individuals.14 Our findings, with 
respect to the interplay between P.g and CRP on 
anti-CCP2 antibody, supports a recent review 
reporting the role of P.g and the proinflammatory 
profile among other factors in the association 
between periodontitis and RA.45
This provides insight into the mechanisms for the 
development of ACPAs. The low ACPA levels in 
one individual with high a quantity of salivary P.g 
DNA and high CRP levels might suggest a suc-
cessful clearing of citrullinated proteins, and 
potentially the lack of genetic risk alleles (i.e. the 
HLA-DRB1 shared epitope), known to associate 
strongly with ACPA production.
Intriguingly, CEP-1 was one of the two most com-
mon ACPA fine-specificities among participants 
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with high P.g DNA. This supports previous find-
ings that PPAD can citrullinate human α-
enolase,12 and our previous report that anti-CEP-1 
antibodies purified from RA patients bind citrul-
linated P.g enolase, forming the basis of a molecu-
lar mimicry hypothesis.11 This hypothesis links 
P.g with RA via citrullination of enolase and 
ACPA production. Our CEP-1 data also support 
recent findings from another German population, 
that periodontitis patients with P.g infection have 
elevated anti-CEP-1 antibody levels.46 Moreover, 
patients with RA with moderate to severe perio-
dontitis and the presence of P.g have elevated 
anti-CEP-1 antibody levels compared with 
patients with RA without periodontitis or P.g.40
The proportion of individuals who were ACPA-
positive in our study (1.8%) is similar to that 
reported from a large Swedish population-repre-
sentative cohort (2.8%).47 With a specificity and 
sensitivity of the anti-CCP2 assay of approxi-
mately 97% and 70%, respectively, and a Germany 
RA prevalence of 1.38%,48 about 25% (4) of our 
study participants who were positive for anti-
CCP2 antibody are expected to have RA, perhaps 
all four individuals who reported rheumatic dis-
ease. Specifically, the individuals who were double 
positive for anti-CCP2 and ACPA fine-specificity 
were likely suffering from RA, since a combina-
tion of ACPAs, use of DMARDs or NSAIDs, and 
high CRP are indicative of an RA diagnosis,49 or 
‘pre-RA’, since elevated anti-CCP2 are known to 
precede the development of RA.50
Furthermore, smoking is the main environmental 
risk factor for ACPA-positive RA,51 and the asso-
ciation between smoking and elevated anti-CCP2 
antibody levels as seen in our study is also a well-
known phenomenon in ‘pre-RA’.52 Studies that 
reported a relation between lower educational 
level and anti-CCP2 antibodies is scarce. 
However, lower socioeconomic status because of 
lower educational attainment has been postulated 
to influence the risk of RA.53 Consistent with our 
findings on factors related to the quantity of P.g, 
others have documented that individuals who 
have a higher alcohol intake harbour more P.g,54 
individuals with T2DM have a high quantity of 
salivary P.g,55 and P.g infection induces local and 
systemic accumulation of leucocytes.56 Aside 
from poor oral health that is generally observed 
in athletes57 and the relation between educa-
tional level and P.g,58 the association of P.g with 
sport activity and occupation has not been previ-
ously reported. Possible explanation for these 
determinants of P.g are alcohol consumption 
resulting in dysbiosis,54 dehydration and local 
drying of the mouth during sporting activity 
reducing antimicrobial activity in the mouth57 
and systemic diseases weakening resistance to 
infection and altering inflammatory response.59
A previous study60 did not observe difference in 
individuals with P.g with RA compared with con-
trols. One possible explanation for the contrasting 
results of Zhang and colleagues60 is the discrepant 
detection of P.g that is related to age.58,61 Our 
study population (average age of 67 years) is older 
than that of Zhang and colleagues (the highest 
age was 65 years and the average age was not 
reported)60 and since saliva P.g increases with 
age;58,61 it is likely that the more detectable P.g in 
our study population partly results in association 
with anti-CCP2/RA.
The strengths of our study were that participants 
were selected with special consideration for sex 
and age strata and were thus representative of a 
well-characterized population of apparently 
healthy individuals. In addition, both exposure 
and outcome were measured objectively, that is, 
in biological samples. Moreover, compared with 
P.g detection from dental plaque or another oral 
niche, salivary P.g captures an aggregate of over-
all P.g exposure, because P.g and other oral bac-
teria are continually shed into the saliva from all 
ecological sites. This study adjusted for several 
factors such as age, sex, smoking, health condi-
tions, and medications, which might have con-
founded our results.
Nevertheless, some points have to be taken into 
account when interpreting our findings. The par-
ticipants’ physicians verified most chronic diseases 
in the EPIC-Potsdam study, but periodontitis 
and rheumatic diseases were not verified because 
the EPIC-Potsdam study was not primarily 
designed to investigate dental health and rheu-
matic diseases. Hence, detailed information, such 
as dental hygiene practices, periodontal care, spe-
cific types of rheumatic disease and their duration 
were not available. Nevertheless, most of the 
covariates and confounders that were considered 
in the analysis were verified. In addition, the 
absence of an association between the quantity of 
P.g and periodontitis could be due the fact that 
periodontitis was self-reported and the poor 
validity of self-reported periodontitis, which is 
well documented,62 and could also be explained 
in part by the fact that periodontitis is a 
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polymicrobial infection and that P.g might be 
absent in some individuals with periodontitis. 
When sampling saliva, participants are often 
instructed not to eat, drink, smoke, or chew gum 
or perform oral hygiene for 30 min prior to sam-
pling. These instructions were not given to our 
participants and these factors might have affected 
yields of gDNA and hence the quantity of P.g. 
However, the fact that gDNA was not signifi-
cantly associated with quantity of P.g in the cur-
rent study, and considering that these factors are 
unlikely to affect CCP2 IgG levels suggest that 
they cannot confound the association between 
P.g and ACPA. Nonetheless, future studies 
should endeavour to standardize saliva presam-
pling, sampling, and postsampling procedures. 
Another drawback is that we did not specifically 
ask participants for RA diagnosis, but ‘rheumatic 
diseases’, which comprise an array of diseases. 
Rheumatoid factor, another important RA bio-
marker was not measured in this study. Additional 
reactivity to fine-specific ACPAs could have been 
determined in all (or larger number of) samples, 
but this was not feasible due to logistic reasons.
A further limitation of our study was its cross-
sectional design. One would expect time lags 
between the colonization of P.g, onset of P.g 
infection, and the development of antibodies to 
citrullinated proteins,31 therefore elevated ACPAs 
may reflect the action of past P.g infection only or 
in consort with present infections. Surely, serum 
IgG to virulence factors in P.g such as arginine-
specific gingipain B or outer membrane antigen 
may be a more suitable marker of both present 
and past P.g infection. The homogenous German 
study population may limit generalizability of this 
current study to other nationalities or ethnic 
groups, although our findings are similar to 
reports in other populations.30 Furthermore, we 
cannot rule out residual and unmeasured con-
founders of the association between P.g and 
ACPAs, such as levels of total IgG. In addition, 
we did not control for confounding between CRP 
and ACPAs since our primary interest was to 
assess the relation of P.g DNA with ACPA levels. 
Moreover, reverse causation due to RA was 
unlikely in the relation of P.g with CCP2 IgG lev-
els since we excluded participants using DMARDs 
as proxy for RA in sensitivity analysis. The focus 
of this study was to investigate the association 
between salivary P.g and serum ACPA levels; 
hence, we did not perform measurements of anti-
P.g antibodies in our participants. The measure-
ment of anti-P.g antibodies levels and investigation 
of their relation to P.g abundance is planned for 
future studies.
Within the limits of our study, salivary P.g DNA 
was linked to serum anti-CCP2 in the presence of 
systemic inflammation, and individuals who were 
anti-CCP2 positive showed additional reactivity 
to fine-specific ACPAs. Individuals with double 
positive anti-CCP2 and ACPA fine-specificity 
also had high P.g and were likely suffering from 
RA. Longitudinal multicentre studies with larger 
study populations to investigate the relationship 
between P.g colonization and infection and 
ACPAs are warranted.
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